Top 5 Drug Type | Count |
---|---|
Small molecule drug | 11 |
Monoclonal antibody | 2 |
Single-chain FV antibody fragment | 1 |
Target |
Mechanism CFB inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date05 Dec 2023 |
Target |
Mechanism Bcr-Abl inhibitors [+1] |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date29 Oct 2021 |
Target |
Mechanism c-Met inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date06 May 2020 |
Start Date22 Oct 2018 |
Sponsor / Collaborator ![]() [+1] |
Start Date01 Aug 2016 |
Sponsor / Collaborator |
Start Date01 Mar 2014 |
Sponsor / Collaborator [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Canakinumab ( IL-1β ) | Cryopyrin-Associated Periodic Syndromes More | Approved |
Ribociclib Succinate ( CDK4 x CDK6 ) | Hormone receptor positive HER2 negative breast cancer More | Approved |
Midostaurin ( FLT3 x PDGFRs x PKC x Syk x VEGFR2 x c-Kit ) | Mast-Cell Leukemia More | Approved |
Eltrombopag Diolamine ( TPO receptor ) | Anemia, Aplastic More | Approved |
Dabrafenib Mesylate ( BRAF x CRAF ) | BRAF V600E Mutation-Positive Solid Tumors More | Approved |